|Bid||12.75 x 800|
|Ask||12.78 x 1800|
|Day's Range||12.32 - 12.98|
|52 Week Range||10.75 - 25.96|
|Beta (3Y Monthly)||2.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We at Insider Monkey have gone over 738 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article, we look at what those funds think of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) based on that […]
Does the June share price for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) reflect what it's really worth? Today, we...
While not a mind-blowing move, it is good to see that the Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) share price has...
On a per-share basis, the New York-based company said it had a loss of 43 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share pricesRead More...
With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week. The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...
Rocket Pharmaceuticals (RCKT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Rocket Pharmaceuticals (RCKT) is a clinical-stage biopharmaceutical company focused on advancing its early-stage gene therapy pipeline across multiple rare diseases with significant unmet demand. According to Rocket Pharmaceuticals, the company’s leading ex-vivo lentiviral vector program in the FA indication is currently in the clinical stage of development. Other research programs are either in the preclinical stage or the discovery stage.
The New York-based company said it had a loss of 40 cents per share. Rocket Pharmaceuticals shares have more than doubled since the beginning of the year. The stock has risen fivefold in the last 12 months. ...